Intercytex Group Plc, a developer of regenerative medicines, has appointed Max Herrmann as its new chief financial officer, effective 19 September 2008. Mr Herrmann joins Intercytex from Fusion IP Plc, a university IP commercialisation company, where he held an independent consulting role for the past 12 months. Prior to this, he spent more than 10 years as an equity analyst, most recently as managing director and head of European pharmaceutical and biotechnology research at ING Equity Markets.
Mr Herrmann qualified as a chartered accountant with Arthur Andersen in 1993. He holds a degree in microbiology from the University of Kent in the UK.
Based in Cambridge, UK, Intercytex develops regenerative medicine products to restore skin and hair.
Copyright 2008 Evernow Publishing Ltd